GlobalData Epidemiologist Report: Global Covid infections pass 67.7 million – vaccinations begin in UK
8 December Globally, the total confirmed cases of Covid-19 have reached over 67,719,000, with more than 1,547,000 deaths and 43,639,000…
Latest Knowledge Bank
-
3 months
-
9 months
-
11 months
-
11 months
-
3 months
-
9 months
-
11 months
-
11 months
Second Covid-19 wave could see worst contraction in global economy in 100 years
11 June The Covid-19 pandemic has led to widespread unemployment and potential bankruptcies of businesses and companies across the world.…
Latest News
View More
Vir and GSK to halt enrolment in Covid-19 antibody trial
Vir Biotechnology and GlaxoSmithKline (GSK) have reported that an independent Data and Safety Monitoring Board (DSMB) has recommended halting enrolment in the VIR-7831 (GSK4182136) arm…
Amgen reports positive data from BLINCYTO study in leukaemia patients
Amgen has reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukaemia (B-ALL).…
Merck withdraws Keytruda from SCLC indication amid FDA crackdown
On 1 March, Merck announced the voluntary withdrawal of its Keytruda (pembrolizumab) immunotherapy for the treatment of patients with metastatic…
Science 37 signs partnership agreement with Medgate for clinical trials
Science 37 has collaborated with digital health and telemedicine company Medgate to further globalise decentralised clinical trials. With presence in…
ObvioHealth and RedHill to begin remote Covid-19 therapy trial
ObvioHealth is set to initiate a Phase II/III study of RedHill Biopharma’s RHB-107 (upamostat) in the US for Covid-19 treatment.…
NIH pauses Covid-19 convalescent plasma trial
The US National Institutes of Health (NIH) has put on hold a trial of convalescent blood plasma in treating patients…
Company A-Z
View More
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
Latest Content
View MoreCOSELA™ (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression, US
COSELA™ (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced bone marrow suppression in adult…
UKONIQ™ (umbralisib) for the Treatment of Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)
UKONIQ™ (umbralisib) is the first and only oral, dual inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1…
New Warehouse Construction at Staufen Headquarters
In the past few months, two new warehouses were erected and put into operation on the IKA premises. IKA continues…